Even as a first-line treatment, atezolizumab monotherapy provides a significantly longer OS than platinum-based chemotherapy in patients with NSCLC with high PD-L1 expression, regardless of the histologic type 8. The gene discussed is CD274; the disease is non-small cell lung carcinoma.